600713 南京医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入41,135,1420.48%53,696,17453,589,66550,221,56445,123,195
减:营业总成本40,346,9910.56%52,651,38552,645,43949,186,22344,249,160
    其中:营业成本38,688,0280.71%50,323,07850,276,36246,962,43042,185,985
               财务费用345,735-13.69%515,588534,751435,170441,844
               资产减值损失(5,366)152.59%(18,267)(6,248)(6,771)(8,618)
公允价值变动收益898----------
投资收益1,144-63.06%4,0188,581(48,645)(87,739)
    其中:对联营企业和合营企业的投资收益(2,725)-355.64%5856,062(519)(2,900)
营业利润691,410-10.39%1,023,4041,007,443934,323845,713
利润总额708,546-7.08%1,003,395978,068906,012838,866
减:所得税费用178,789-10.04%260,275265,259190,092228,314
净利润529,757-6.04%743,120712,809715,920610,552
减:非控股权益127,7854.81%172,492134,983120,252105,369
股东净利润401,971-9.03%570,628577,826595,668505,183

市场价值指针
每股收益 (元) *0.310-8.82%0.4380.4450.4750.485
每股派息 (元) *----0.1700.1600.1400.120
每股净资产 (元) *5.3233.83%5.2164.9124.5794.422
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容